title: Successful treatment of relapsed anaplastic large cell lymphoma with vinblastine monotherapy and allo-HSCT with reduced intensity conditioning regimen.
abstract: Relapsed anaplastic large cell lymphoma (ALCL) is chemosensitive, but recurrence is common. Although vinblastine (VLB) monotherapy is an effective treatment for relapsed ALCL, the optimal treatment duration is unknown, and some patients experience further relapse after completing the treatment. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is also an effective treatment for relapsed ALCL, although transplant-related toxicity is a problem. Here, we report an 11-year-old patient with relapsed ALCL who underwent induction therapy with VLB monotherapy and achieved complete remission (CR) after 12 courses. CR was confirmed on positron emission tomography-computed tomography. The patient then underwent allo-HSCT with reduced intensity conditioning (fludarabine, melphalan, and low-dose total body irradiation). He developed grade II acute graft-versus-host disease (GVHD), which was successfully treated with methylprednisolone. There was no evidence of chronic GVHD. He has remained in CR without any complications for 19 months after allo-HSCT.
authors.affiliation: Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Miyagaki
authors.affiliation: Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto.
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Imamura
authors.affiliation: Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto.
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Okumura
authors.affiliation: Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto.
authors.forename: Ikuyo
authors.initials: I
authors.lastname: Ito
authors.affiliation: Department of Pediatrics, Matsushita Memorial Hospital, Moriguchi, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Fujiki
authors.affiliation: Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto.
authors.forename: Shinya
authors.initials: S
authors.lastname: Osone
authors.affiliation: Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto.|Department of Pediatrics, Matsushita Memorial Hospital, Moriguchi, Japan.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ishida
authors.affiliation: Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto.
authors.forename: Hajime
authors.initials: H
authors.lastname: Hosoi
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D001521:Behavior Therapy; D002648:Child; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D012074:Remission Induction; D014184:Transplantation, Homologous; D014747:Vinblastine / Q000627:therapeutic use*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine
keywords: allogeneic hematopoietic stem cell transplantation; anaplastic large cell lymphoma; reduced intensity conditioning; vinblastine